On The Rise and Fall of Psychedelic Research: Ethical Lessons For Its Revival
by Clara Raithel
This is the first post in our series on the consequences of outside influences on the performance and communication of science.
More than fifty years after the criminalization of psychedelic drugs, psychedelic research is experiencing what many call a “renaissance” [1,2]. Researchers across the world conduct clinical trials testing the efficacy of psychedelic drugs, such as ecstasy (MDMA), mescaline, lysergic acid diethylamide (LSD), and psilocybin, as a form of treatment against various mental diseases, with some pointing towards therapeutic potential [3,4]. This increase in scientific interest is not a first: in the 1950s and 1960s, researchers first got their hands on psychedelics and saw great potential in these compounds to allow for a breakthrough in mental health science. However, instead of describing a breakthrough, psychedelic drugs gained a bad reputation and were effectively banned in 1970 when the US government initiated its “war on drugs”. How did the perception of psychedelic drugs change so drastically? Contemporary psychedelic scientists often put the blame on counterculture figures. The most prominent scapegoat is Dr. Timothy Leary, a Harvard psychologist who lightheartedly shared the drug at parties, evoking a bulk of negative press surrounding LSD that ultimately justified the “war on drugs” in the public eye. But explaining the bad reputation of past psychedelic research takes more than just pointing fingers at “bad scientists”.
Read More